NEW YORK, Jan. 13, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
IntroductionThis analysis examines the historical and forecast performance for Shire in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
* Gain insight into Shire's strategic outlook across the next 6 years* Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
HighlightsStrategic insight into the prospects for Shire over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered* Benchmark Shire's performance against key rivals in the prescription pharmaceutical sector* Shire has pulled off the feat of overcoming the loss of its largest product by a long way, Adderall XR. Assess the strategies used to achieve this.* Diversifying away from key historical markets such as ADHD, Shire has built an enviable portfolio of treatments for rare genetic disorders.
To order this report:: Shire plc: PharmaVitae Profile
Copyright©2010 PR Newswire.
All rights reserved